GALNS

Across TCGA pan-cancer cohorts, GALNS mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GALNS data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GALNS mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GALNS expression acts as an unfavorable survival marker.

PDAC, LUAD, and CCRCC are the cancer types where GALNS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.437	0.903	<.001	44	view →
LUAD	DFS	Quartile	III,IV	0.372	0.968	.002	28	view →
CCRCC	DFS	Median	II,III,IV	0.235	0.887	.005	18	view →
LSCC	DFS	Median	All	0.893	0.971	.014	13	view →
HNSC	OS	Median	III,IV	0.585	0.803	.010	7	view →
COAD	DFS	Median	III,IV	0.892	1.000	.034	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GALNS–PDAC (DFS)

Open the PDAC breakdown →